Scientists Discover How Alzheimer's Spreads Through the Brain,and a Way to Slow It
Scientists have identified a key mechanism behind how Alzheimer's disease spreads through the brain, opening a new path to treatments that could slow the disease rather than simply clearing away toxic proteins after damage occurs. Researchers at the University of Utah Health discovered that a brain protein called Arc, which normally helps neurons communicate, may inadvertently be helping the disease progress by carrying toxic tau from damaged brain cells into healthy ones.
How Does Tau Spread Between Brain Cells?
Alzheimer's disease is driven by the buildup of tau, a protein that clumps into sticky tangles inside neurons, disrupting their internal machinery and eventually killing them. As tau spreads to new regions of the brain, memory loss and cognitive decline worsen. To understand how this spread happens, researchers compared mice with Alzheimer's-like disease to mice that lacked the Arc protein.
The team found that Arc normally packages itself into tiny structures called extracellular vesicles, which shuttle between neurons carrying important cellular signals. However, toxic tau can exploit this natural communication system by hitching a ride inside these same vesicles. Once inside, tau travels from a diseased neuron into a healthy one, where it can trigger new tangles to form.
"When we removed Arc, we saw that the transfer of tau was severely, severely reduced. It was almost gone," explained Mitali Tyagi, postdoctoral research associate at Washington University in St. Louis and first author of the study.
Mitali Tyagi, Postdoctoral Research Associate, Washington University in St. Louis
When Arc was removed from the mice, the vesicles carried far less tau, and the disease no longer spread effectively between neurons. This finding suggests a promising new target for future therapies: intercepting tau-carrying vesicles after they leave diseased neurons but before they reach healthy ones.
Why Simply Blocking Arc Isn't the Answer?
The results were not entirely straightforward. Arc also appears to do the positive job of helping neurons survive longer in the early stages of disease by allowing them to expel excess toxic tau. In mice without Arc, toxic tau remained trapped inside neurons, causing those already sick cells to die more quickly.
This dual role suggests that simply blocking Arc altogether may not be an effective treatment strategy. Instead, researchers believe future treatments should focus on preventing the tau-carrying vesicles from entering healthy neurons while still allowing damaged cells to expel their toxic waste.
"For decades, research has focused on the toxic buildup of tau inside neurons; this study reframes the problem by showing how tau may exploit the brain's own communication machinery, specifically the Arc protein and its extracellular vesicle system, to spread between cells," said Dr. Christopher U. Missling, president of Anavex Life Sciences.
Dr. Christopher U. Missling, President, Anavex Life Sciences
What Evidence Suggests This Works in Humans?
The team also detected extracellular vesicles containing both Arc and tau in human brain tissue, suggesting the same process could be at work in people. However, researchers caution that significant further study, especially on humans, is needed before the findings could lead to any treatment.
"Most of the work we've been doing is in mice, not in humans. We have some clues that whatever is happening in these mice could also be happening in humans, but we don't know that yet. And we're far away from saying that we're developing a treatment for anything," stated Jason Shepherd, professor of neurobiology at University of Utah Health and senior author of the study.
Jason Shepherd, Professor of Neurobiology, University of Utah Health
Steps to Understanding Alzheimer's Prevention Strategies
While this research focuses on slowing disease progression, experts emphasize that a comprehensive approach to brain health may help reduce dementia risk. Here are key strategies being explored:
- Targeting Tau Transport: Future therapies may intercept tau-containing extracellular vesicles after they leave diseased neurons but before they reach healthy ones, potentially slowing disease spread without eliminating the protein entirely.
- Metabolic Health Management: Some research suggests that maintaining healthy glucose metabolism and cardiovascular function may support brain health, though more evidence is needed to confirm direct dementia prevention benefits.
- Early Detection and Monitoring: Identifying individuals with mild cognitive impairment early may allow for intervention before widespread tau spread occurs, making treatment more effective.
What's the Timeline for New Treatments?
The discovery offers a promising new target for future therapies, but researchers stress that much more work lies ahead. The study, titled "Arc mediates intercellular tau transmission via extracellular vesicles," was published in the journal Cell and was supported by the National Institutes of Health, the Alzheimer's Association, and several other research organizations.
One promising possibility would be to intercept tau-containing extracellular vesicles after they leave diseased neurons but before they reach healthy ones. While such an approach would not reverse existing brain damage, it could potentially slow or prevent further spread of Alzheimer's disease.
"If we could target these particular extracellular vesicles, that would be a really useful therapy strategy. For someone with early-onset Alzheimer's or dementia, if we could stop the spread, then we could prevent further damage and cognitive decline," noted Jason Shepherd.
Jason Shepherd, Professor of Neurobiology, University of Utah Health
The research reframes how scientists think about Alzheimer's treatment. Rather than focusing solely on clearing away toxic proteins after damage is done, future therapies may focus on preventing the disease from spreading to new brain regions in the first place. This shift in perspective could lead to more effective interventions for people in the early stages of cognitive decline.